Mads Laustsen
Direktor/Vorstandsmitglied bei NANOFORM FINLAND OYJ
Aktive Positionen von Mads Laustsen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NANOFORM FINLAND OYJ | Direktor/Vorstandsmitglied | 01.01.2019 | - |
Independent Dir/Board Member | 01.01.2019 | - | |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017. | Direktor/Vorstandsmitglied | 01.08.2017 | - |
Vorstandsvorsitzender | 01.08.2017 | - | |
Gründer | 01.08.2017 | - | |
Synklino ApS
Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
VenomAid Diagnostics ApS
VenomAid Diagnostics ApS Medical/Nursing ServicesHealth Services VenomAid Diagnostics ApS provides diagnostic test services for snake bites. The company is based in Kongens Lyngby, Denmark. The Danish company was founded by Cecilie Knudsen, Søren H. Dam, Jonas A. Jürgensen, Andreas Hougaard Laustsen. Jonas A. Jürgensen has been the CEO since incorporation. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Mads Laustsen
Ehemalige bekannte Positionen von Mads Laustsen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Direktor/Vorstandsmitglied | 01.01.2014 | 01.01.2019 |
Corporate Officer/Principal | 01.01.2014 | 01.01.2019 | |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | 01.01.1994 | 01.01.2001 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01.01.1985 | 01.01.1993 |
Cmc Biologics A/S | Vorstandsvorsitzender | - | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
░░░ ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mads Laustsen
Technical University of Denmark | Undergraduate Degree |
Statistik
International
Dänemark | 10 |
Vereinigte Staaten | 2 |
Finnland | 2 |
Operativ
Director/Board Member | 6 |
Corporate Officer/Principal | 4 |
Chief Executive Officer | 3 |
Sektoral
Health Technology | 7 |
Health Services | 3 |
Process Industries | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
NANOFORM FINLAND OYJ | Health Technology |
Private Unternehmen | 8 |
---|---|
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Synklino ApS
Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | Health Services |
Cmc Biologics A/S | |
VenomAid Diagnostics ApS
VenomAid Diagnostics ApS Medical/Nursing ServicesHealth Services VenomAid Diagnostics ApS provides diagnostic test services for snake bites. The company is based in Kongens Lyngby, Denmark. The Danish company was founded by Cecilie Knudsen, Søren H. Dam, Jonas A. Jürgensen, Andreas Hougaard Laustsen. Jonas A. Jürgensen has been the CEO since incorporation. | Health Services |
- Börse
- Insiders
- Mads Laustsen
- Erfahrung